Therapeutical interference with the epigenetic landscape of germ cell tumors: a comparative drug study and new mechanistical insights.

Abstract

BACKGROUND:

Type II germ cell tumors (GCT) are the most common solid cancers in males of age 15 to 35 years. Treatment of these tumors includes cisplatin-based therapy achieving high cure rates, but also leading to late toxicities. As mainly young men are suffering from GCTs, late toxicities play a major role regarding life expectancy, and the development of therapy resistance emphasizes the need for alternative therapeutic options. GCTs are highly susceptible to interference with the epigenetic landscape; therefore, this study focuses on screening of drugs against epigenetic factors as a treatment option for GCTs.

RESULTS:

We present seven different epigenetic inhibitors efficiently decreasing cell viability in GCT cell lines including cisplatin-resistant subclones at low concentrations by targeting epigenetic modifiers and interactors, like histone deacetylases (Quisinostat), histone demethylases (JIB-04), histone methyltransferases (Chaetocin), epigenetic readers (MZ-1, LP99) and polycomb-repressive complexes (PRT4165, GSK343). Mass spectrometry-based analyses of the histone modification landscape revealed effects beyond the expected mode-of-action of each drug, suggesting a wider spectrum of activity than initially assumed. Moreover, we characterized the effects of each drug on the transcriptome of GCT cells by RNA sequencing and found common deregulations in gene expression of ion transporters and DNA-binding factors. A kinase array revealed deregulations of signaling pathways, like cAMP, JAK-STAT and WNT.

CONCLUSION:

Our study identified seven drugs against epigenetic modifiers to treat cisplatin-resistant GCTs. Further, we extensively analyzed off-target effects and modes-of-action, which are important for risk assessment of the individual drugs.

• Authors: Melanie R Müller, Aaron Burmeister, Margaretha A Skowron, Alexa Stephan, Felix Bremmer, Gamal A Wakileh, Patrick Petzsch, Karl Köhrer, Peter Albers, Daniel Nettersheim
• Journal: Clinical epigenetics (Clin Epigenetics) Vol. 14 Issue 1 Pg. 5 (01 07 2022) ISSN: 1868-7083 [Electronic] Germany
• PMID: 34996497 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2022. The Author(s).

Chemical References

• Antineoplastic Agents
• Cisplatin

Topics

• Adolescent
• Adult
• Antineoplastic Agents (therapeutic use, toxicity)
• Cell Line (drug effects)
• Cell Survival (drug effects)
• Cisplatin (therapeutic use, toxicity)
• Epigenesis, Genetic (drug effects)
• Humans
• Male
• Molecular Targeted Therapy
• Neoplasms, Germ Cell and Embryonal (drug therapy)
• Testicular Neoplasms (drug therapy)
• Young Adult